Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Impressive results, attractive valuation - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 19, 2000

    Sun Pharma: Impressive results, attractive valuation

    Sun Pharma has reported results as per expectations with net profits up 41% on the back of 35% growth in the topline. The topline has been led by a 79% increase in bulk drug sales apart from a 20% increase in the formulation sales. This is due to the fact that Gujarat Lyka (which produces bulk drugs) has been amalgamated with Sun Pharma in the current year. This also explains the drop in operating margins since the contribution of bulk drugs to the total turnover has increased to 32% in the current year from 24% last year.

    (Rs m) 2QFY00 2QFY01 Change
    Sales 1,129 1,519 34.5%
    Other Income 6 33 469.0%
    Expenditure 856 1,179 37.8%
    Operating Profit (EBDIT) 273 340  
    Operating Profit Margin (%) 24.2% 22.4%  
    Interest 6 (6) -198.4%
    Depreciation 30 35 16.6%
    Profit before Tax 243 344 41.9%
    Other Adjustments      
    Tax 15 22  
    Profit after Tax/(Loss) 228 322 41.3%
    Net profit margin (%) 20.2% 21.2%  
    Earnings per share* 19.50 27.56  

    However, the growth in formulation sales by 20% is impressive when seen in the light of the fact that the overall industry growth for the first five months has been in the range of 11% only. Sun Pharmaceuticals manufactures formulations in niche segments such as psychiatry, cardiovascular, gastroentology and neurology.

    What is particularly encouraging for the company is the fact that formulation exports have picked up in the second quarter. Overall formulation exports in the second quarter (this includes the performance of its 99.38% subsidiary Sun Pharmaceutical Exports) have risen by almost 50% in the second quarter vis-ŕ-vis a 39% growth in the full first half. Thus the company has successfully fine–tuned its strategy of exports of finished dosage forms.

    Also, Sun has been extremely aggressive in the launch of new products in the domestic market with almost 24 new product launches in its niche areas, slated for the current year itself (10 of these have already been launched). The company derives almost 40% of its revenues from products introduced in the past five years. Consequently its exposure to revenues accruing from products under the DPCO is a relatively low 19% of domestic formulation sales.

    Perhaps the only area of concern is the continuing losses of its US based affiliate Caraco Pharma, which is the company’s vehicle for launch of generics. (Sun has invested Rs 288.63 m towards equity and Rs 252.86 m towards debt in Caraco, which has registered a loss of over $ 9.5 m for the year ended December 1999.) Caraco has submitted around nine abbreviated new drug applications (ANDA) which are awaiting US FDA approval. Besides, Caraco needs further cash infusion for which it is planning to raise debt in the US market. Sun has however not provided for this dimunition in the value of its investments in the current year as the management feels that in view of the future growth potential and long term nature of investments.

    The stock has come off almost 25% over the last six months to its current levels of 448. The fall in valuation is partially due to the fact that the overall valuations in the market have come down over the last one week and partially due to the concerns over its US–based affiliate Caraco’s losses. At the current valuation the stock rules at 16.25 times FY2001 earnings.

    The management has already stated its intention to amalgamate Sun Pharma Exports, the company’s 99.38% subsidiary into Sun Pharma. This would add roughly another Rs 130 m to the company’s expected profits of Rs 1265 m in FY2001. The per share earnings work out to around Rs 29.85 and this implies an earning multiple of 15 at current valuations. If one were to deduct the entire losses accrued by Caraco so far (i.e. Rs 437 m) the earnings work out Rs 20.50 and the current stock price implies an earnings multiple of 22 times.



    Equitymaster requests your view! Post a comment on "Sun Pharma: Impressive results, attractive valuation ". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 02:08 PM


    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts